Logo image of VTAK

CATHETER PRECISION INC (VTAK) Stock Fundamental Analysis

USA - NYSE Arca - NYSEARCA:VTAK - US74933X7084 - Common Stock

2.235 USD
-0.29 (-11.49%)
Last: 12/15/2025, 8:04:00 PM
2.22 USD
-0.01 (-0.67%)
After Hours: 12/15/2025, 8:04:00 PM
Fundamental Rating

2

VTAK gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 187 industry peers in the Health Care Equipment & Supplies industry. VTAK has a bad profitability rating. Also its financial health evaluation is rather negative. VTAK is valued quite expensively, but it does show have an excellent growth rating.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

VTAK had negative earnings in the past year.
In the past year VTAK has reported a negative cash flow from operations.
In the past 5 years VTAK always reported negative net income.
VTAK had a negative operating cash flow in each of the past 5 years.
VTAK Yearly Net Income VS EBIT VS OCF VS FCFVTAK Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -20M -40M -60M

1.2 Ratios

VTAK has a Return On Assets of -94.12%. This is in the lower half of the industry: VTAK underperforms 78.61% of its industry peers.
The Return On Equity of VTAK (-354.30%) is worse than 78.61% of its industry peers.
Industry RankSector Rank
ROA -94.12%
ROE -354.3%
ROIC N/A
ROA(3y)-156.76%
ROA(5y)-139.44%
ROE(3y)-270.77%
ROE(5y)-233.22%
ROIC(3y)N/A
ROIC(5y)N/A
VTAK Yearly ROA, ROE, ROICVTAK Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 -100 -200 -300

1.3 Margins

VTAK has a better Gross Margin (92.33%) than 98.40% of its industry peers.
The Profit Margin and Operating Margin are not available for VTAK so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 92.33%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
VTAK Yearly Profit, Operating, Gross MarginsVTAK Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024 0 -50K -100K -150K

More info and screens

1

2. Health

2.1 Basic Checks

VTAK does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for VTAK has been increased compared to 1 year ago.
VTAK has a worse debt/assets ratio than last year.
VTAK Yearly Shares OutstandingVTAK Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 100K 200K 300K 400K
VTAK Yearly Total Debt VS Total AssetsVTAK Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 10M 20M 30M

2.2 Solvency

Based on the Altman-Z score of -18.05, we must say that VTAK is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -18.05, VTAK is doing worse than 88.77% of the companies in the same industry.
VTAK has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
VTAK has a better Debt to Equity ratio (0.00) than 73.26% of its industry peers.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -18.05
ROIC/WACCN/A
WACC7.59%
VTAK Yearly LT Debt VS Equity VS FCFVTAK Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 10M -10M 20M -20M -30M

2.3 Liquidity

A Current Ratio of 0.44 indicates that VTAK may have some problems paying its short term obligations.
Looking at the Current ratio, with a value of 0.44, VTAK is doing worse than 93.58% of the companies in the same industry.
A Quick Ratio of 0.43 indicates that VTAK may have some problems paying its short term obligations.
Looking at the Quick ratio, with a value of 0.43, VTAK is doing worse than 92.51% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 0.44
Quick Ratio 0.43
VTAK Yearly Current Assets VS Current LiabilitesVTAK Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M

More info and screens

8

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 70.00% over the past year.
The Revenue has grown by 37.61% in the past year. This is a very strong growth!
The Revenue has been growing by 167.26% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)70%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%93.12%
Revenue 1Y (TTM)37.61%
Revenue growth 3Y167.27%
Revenue growth 5YN/A
Sales Q2Q%127.96%

3.2 Future

The Earnings Per Share is expected to grow by 40.75% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 312.31% on average over the next years. This is a very strong growth
EPS Next Y96.27%
EPS Next 2Y40.75%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year533.33%
Revenue Next 2Y312.31%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
VTAK Yearly Revenue VS EstimatesVTAK Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2M 4M 6M 8M 10M
VTAK Yearly EPS VS EstimatesVTAK Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2023 2024 2025 2026 -200K -400K -600K -800K -1M

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

VTAK reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year VTAK is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
VTAK Price Earnings VS Forward Price EarningsVTAK Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
VTAK Per share dataVTAK EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -20 -40 -60

4.3 Compensation for Growth

A more expensive valuation may be justified as VTAK's earnings are expected to grow with 40.75% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y40.75%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

VTAK does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

CATHETER PRECISION INC

NYSEARCA:VTAK (12/15/2025, 8:04:00 PM)

After market: 2.22 -0.01 (-0.67%)

2.235

-0.29 (-11.49%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)11-13 2025-11-13/amc
Earnings (Next)03-19 2026-03-19/amc
Inst Owners0.58%
Inst Owner Change-99.99%
Ins Owners0.74%
Ins Owner Change4.3%
Market Cap3.73M
Revenue(TTM)600.00K
Net Income(TTM)-24.06M
Analysts85.71
Price Target38.76 (1634.23%)
Short Float %3.01%
Short Ratio0.26
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-59.17%
Min Revenue beat(2)-65.07%
Max Revenue beat(2)-53.27%
Revenue beat(4)0
Avg Revenue beat(4)-65.2%
Min Revenue beat(4)-91.15%
Max Revenue beat(4)-51.31%
Revenue beat(8)0
Avg Revenue beat(8)-68.97%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 6.22
P/FCF N/A
P/OCF N/A
P/B 0.55
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-73.84
EYN/A
EPS(NY)-0.33
Fwd EYN/A
FCF(TTM)-6.14
FCFYN/A
OCF(TTM)-6.13
OCFYN/A
SpS0.36
BVpS4.07
TBVpS-9.86
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -94.12%
ROE -354.3%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 92.33%
FCFM N/A
ROA(3y)-156.76%
ROA(5y)-139.44%
ROE(3y)-270.77%
ROE(5y)-233.22%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.02
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 1.08%
Cap/Sales 3.83%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.44
Quick Ratio 0.43
Altman-Z -18.05
F-Score5
WACC7.59%
ROIC/WACCN/A
Cap/Depr(3y)3.63%
Cap/Depr(5y)N/A
Cap/Sales(3y)51.53%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)70%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%93.12%
EPS Next Y96.27%
EPS Next 2Y40.75%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)37.61%
Revenue growth 3Y167.27%
Revenue growth 5YN/A
Sales Q2Q%127.96%
Revenue Next Year533.33%
Revenue Next 2Y312.31%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-14.48%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y58.92%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y58.89%
OCF growth 3YN/A
OCF growth 5YN/A

CATHETER PRECISION INC / VTAK FAQ

What is the ChartMill fundamental rating of CATHETER PRECISION INC (VTAK) stock?

ChartMill assigns a fundamental rating of 2 / 10 to VTAK.


What is the valuation status of CATHETER PRECISION INC (VTAK) stock?

ChartMill assigns a valuation rating of 1 / 10 to CATHETER PRECISION INC (VTAK). This can be considered as Overvalued.


Can you provide the profitability details for CATHETER PRECISION INC?

CATHETER PRECISION INC (VTAK) has a profitability rating of 1 / 10.


How financially healthy is CATHETER PRECISION INC?

The financial health rating of CATHETER PRECISION INC (VTAK) is 1 / 10.


What is the earnings growth outlook for CATHETER PRECISION INC?

The Earnings per Share (EPS) of CATHETER PRECISION INC (VTAK) is expected to grow by 96.27% in the next year.